Co-Diagnostics, Inc. to Participate at FIME 2024 in Miami Beach, June 19-21
Rhea-AI Summary
Co-Diagnostics, a molecular diagnostics firm, will participate in the FIME 2024 trade show in Miami Beach, Florida from June 19-21. The company, known for its unique, patented platform for developing molecular diagnostic tests, will be hosted at the Utah booth. FIME is a premier medical trade expo attracting over 15,000 professionals and exhibitors from 116 countries. Co-Diagnostics will showcase its new Co-Dx PCR platform, which is under review by the FDA for Over-the-Counter (OTC) clearance. Attendees can visit Booth S61 to learn more about Co-Dx products, including the Co-Dx PCR Pro instrument and associated tests, which are currently under FDA review but not yet available for sale.
Positive
- None.
Negative
- None.
News Market Reaction – CODX
On the day this news was published, CODX gained 5.52%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
FIME is described as the
The Company will be participating in the
To learn more about the event, please visit here. Attendees interested in learning more about Co-Dx and its products, including its upcoming Co-Dx PCR Pro instrument and tests, are invited to visit the Company at Booth S61.
*The Co-Dx PCR platform (including the PCR Home™, PCR Pro™, mobile app, and all associated tests) is subject to review by the FDA and/or other regulatory bodies and is not yet available for sale. The Co-Dx PCR Pro instrument and Co-Dx COVID-19 Test are currently under review by the FDA.
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a
View original content to download multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-inc-to-participate-at-fime-2024-in-miami-beach-june-19-21-302175867.html
SOURCE Co-Diagnostics